Previous 10 | Next 10 |
Shares of Constellation Pharmaceuticals (CNST) have lost roughly a quarter of their value since my August 2018 article delved into early clinical evidence for its BET inhibitor CPI-060 in myelofibrosis and other assets of interest. While a small pilot position was suggested, I also stated re...
The following slide deck was published by Constellation Pharmaceuticals, Inc. in conjunction with this Read more ...
Gainers: Teekay Offshore Partners L.P. (NYSE: TOO ) +32% . BioCardia ( OTCQB:BCDA ) +25% . Roan Resources (NYSE: ROAN ) +21% . Conformis (NASDAQ: CFMS ) +18% . Constellation Pharmaceuticals (NASDAQ: CNST ) +15% . Pintec Technology Holdings (NASDAQ: PT ) +13% . Geron Corporation...
Constellation Pharmaceuticals (NASDAQ: CNST ) announces a private placement of $65M with a group of institutional investors. More news on: Constellation Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
CAMBRIDGE, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that it has entered into a securities purc...
CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Jigar Raythatha, CEO, will present a...
Constellation Pharmaceuticals (NASDAQ: CNST ) has dosed the first patient in a Phase 1/2 clinical trial of CPI-0209. More news on: Constellation Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
CAMBRIDGE, Mass., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company has dosed the first patient...
Atreca (NASDAQ: BCEL ) initiated with Buy rating and $30 (61% upside) price target at Roth Capital. More news on: Atreca, Inc., Constellation Pharmaceuticals, Inc., Ovid Therapeutics Inc., Healthcare stocks news, Stocks on the move, , Read more ...
CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in two...
News, Short Squeeze, Breakout and More Instantly...
Constellation Pharmaceuticals Inc. Company Name:
CNST Stock Symbol:
NASDAQ Market:
Constellation Pharmaceuticals Inc. Website:
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...